Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Bintrafusp alfa + FPV-CV301 + MVA-BN-CV301 + SX-682|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bintrafusp alfa||MSB0011359C|M7824||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112 TGFBR2 Antibody 3||Bintrafusp alfa is a human PD-L1 (CD274) antibody fused with transforming growth factor-beta (TGF-beta, TGFBR2) receptor II extracellular domain, which blocks two immuno-inhibitory pathways simultaneously, therefore enhances anti-tumor immunity (PMID: 29298798, PMID: 32461347).|
|FPV-CV301||FPV-CV-301|FPV Vaccine CV301|FPV CV301|FPV CV 301||FPV-CV301 is a booster cancer vaccine derived from recombinant fowlpox virus encoding CEA and MUC-1, as well as B7-1, ICAM-1, and LFA-3 costimulatory molecules (TRICOM), which potentially induces cytotoxic T-cell response against tumor cells expressing CEA and MUC-1 (NCI Thesaurus).|
|MVA-BN-CV301||MVA-BN CV301|MVA BN CV301|MVA-BN-CV-301||MVA-BN-CV301 is a priming cancer vaccine derived from a modified vaccinia Ankara-Bavarian Nordic (MVA-BN) virus encoding CEA and MUC-1, as well as B7-1, ICAM-1, and LFA-3 costimulatory molecules (TRICOM), which potentially induces cytotoxic T-cell response against tumor cells expressing CEA and MUC-1 (NCI Drug Dictionary).|
|SX-682||SX682|SX 682||CXCR Antagonist 4||SX-682 is an inhibitor of the C-X-C chemokine receptor types, CXCR1 and CXCR2, resulting in reduced neutrophil chemotaxis and decreased tumor cell tumor cell migration (PMID: 31848188).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04574583||Phase Ib/II||Bintrafusp alfa + FPV-CV301 + MVA-BN-CV301 + SX-682||Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)||Active, not recruiting||USA||0|